Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment ...

Retrieved on: 2020-12-02 17:26:15

Tags for this article:

Health sciences

Health

Medicine

Monoclonal antibodies

Elusys Therapeutics

Obiltoxaximab

Anthrax

Biomedical Advanced Research and Development Authority

Anthim

Monoclonal antibody therapy

Bacillus anthracis

Antibiotic

Elusys Therapeutics Inc.

PARSIPPANY

United States

Click the tags to see associated articles and topics

Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment .... View article details on HISWAI: https://pipelinereview.com/index.php/2020120276707/Antibodies/Obiltoxaximab-Receives-Marketing-Authorization-From-European-Commission-For-The-Treatment-Of-Inhalation-Anthrax.html

Excerpt

... Commission has approved obiltoxaximab, the company's <b>monoclonal antibody</b> (mAb) anthrax antitoxin for the treatment of inhalation anthrax.

Article found on: pipelinereview.com

View Original Article